Founded in 2010, Advanced BioDesign is a clinical stage company developing a highly promising therapy for cancer with high unmet medical needs. Advanced Biodesign has developed a therapeutic approach based on a selective inhibition of ALDH enzymes.
Advanced Biodesign project consist in the development of small-molecule that will selectively inhibit specific ALDH enzyme. By targeting this family of enzyme, will block specifically the intracellular mechanism of detoxification that cancerous cells have developed in order to escape form the programmed cell death called apoptosis.
Advanced Biodesign project consist in the development of small-molecule that will selectively inhibit specific ALDH enzyme. By targeting this family of enzyme, will block specifically the intracellular mechanism of detoxification that cancerous cells have developed in order to escape form the programmed cell death called apoptosis.
Location: France, Auvergne-Rhône-Alpes, Saint-Priest
Employees: 11-50
Total raised: $9.79M
Founded date: 2010
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.02.2020 | - | $9.79M | - |
Mentions in press and media 2
| Date | Title | Description |
| 25.02.2020 | Advanced BioDesign Raises Additional €9M Financing | Advanced BioDesign, a Lyon, France-based developer of new therapies for overcoming tumor resistant cancers, raised an additional €9M ($9.8M) financing. Existing backer Xerys Funds made the investment. This is the largest funding raised by A... |
| - | Advanced BioDesign | “Advanced BioDesign is a young innovative company developing solutions addressed at solving issues on cell apoptosis, which is at the origin of its R&D in discovery of anticancer molecules and on detection of infectious diseases.” |